Corcept Therapeutics
CORT
422 hedge funds and large institutions have $7.15B invested in Corcept Therapeutics in 2026 Q2 according to their latest regulatory filings, with 129 funds opening new positions, 145 increasing their positions, 110 reducing their positions, and 54 closing their positions.
273% more call options, than puts
Call options by funds: $163M | Put options by funds: $43.7M
139% more first-time investments, than exits
New positions opened: 129 | Existing positions closed: 54
123% more capital invested
Capital invested by funds: $3.2B → $7.15B (+$3.94B)
32% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 110
20% more funds holding
Funds holding: 352 → 422 (+70)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
1.89% more ownership
Funds ownership: 74.8% → 76.69% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$131M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$42.9M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$42M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$32.8M |
| 5 |
PA
Perceptive Advisors
New York
|
+$21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$27.2M |
| 2 |
Jane Street
New York
|
-$25.4M |
| 3 |
Renaissance Technologies
New York
|
-$25.4M |
| 4 |
Millennium Management
New York
|
-$24.5M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$20.8M |
CORT Hedge Fund Activity: Q2 2026 in Review
422 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2026, worth a combined $7.15B — up 123% from $3.2B a quarter earlier.
Buyers outnumbered sellers: 129 funds opened new CORT positions and 54 closed out — a net gain of 75 holders — while 145 added to existing stakes and 110 trimmed.
The largest buyer was AQR Capital Management, adding an estimated $131M. The largest seller was Sio Capital Management, exiting entirely with an estimated $27.2M sold.
- 422 institutional investors held Corcept Therapeutics (CORT) as of Q2 2026, up from 352 in Q1 2026.
- Funds reported $7.15B of Corcept Therapeutics stock for Q2 2026, up 123% quarter-over-quarter.
- 129 funds opened new Corcept Therapeutics positions in Q2 2026 and 54 closed out, a net change of +75 holders.
- The largest Corcept Therapeutics buyer in Q2 2026 was AQR Capital Management, an estimated $131M added.
- The largest Corcept Therapeutics seller in Q2 2026 was Sio Capital Management, an estimated $27.2M sold.
Based on aggregated 13F filings for Q2 2026.